Emerging Infectious Disease Categories (NIAID) 1 of 3

Similar documents
Pandemic Influenza: Hype or Reality?

USAID s approach to the control of avian and pandemic influenza

OIE Situation Report for Highly Pathogenic Avian Influenza

Humanitarian Initiative to Prepare for a Pandemic Influenza Emergency (HIPPIE) Ron Waldman, MD Avian and Pandemic Influenza Unit USAID/Washington

Middle East respiratory syndrome coronavirus (MERS-CoV) and Avian Influenza A (H7N9) update

Chapter 38 Viral Infections

Influenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong

OIE Situation Report for Avian Influenza

Before and during influenza pandemics

Emerging global health threats of animal origin

Avian Influenza (Bird Flu) Fact Sheet

PUBLIC HEALTH SIGNIFICANCE SEASONAL INFLUENZA AVIAN INFLUENZA SWINE INFLUENZA

Where Health Care Meets Policy. with Dr. Mike Magee

H5N1 avian influenza: timeline

RISK OF WORLDWIDE PANDEMIC AND STATE OF PANDEMIC PREPAREDNESS: FOCUS ON INFLUENZA

ISPUB.COM. Bird flu: A Throbbing Stone In An Infectious Era. T Wadhwa, P Kumar Thirupathi EPIDEMIOLOGY TRANSMISSION FROM AVIAN TO HUMAN

SEA/CD/154 Distribution : General. Avian Influenza in South-East Asia Region: Priority Areas for Research

Influenza and the Poultry Link

Influenza: The Threat of a Pandemic

Research Issues in Animal Surveillance and Pandemic Planning

GLOBAL AND REGIONAL SITUATION OF AVIAN INFLUENZA

Avian Influenza Prevention and Preparedness: Global and Regional Strategies and Actions

OIE Situation Report for Avian Influenza

The Demographic Impact of an Avian Flu Pandemic

Pandemic Influenza Preparedness

EPIDEMICS AND PANDEMICS: PREDICTION, PREVENTION, CONTROL?

The Current Status of the Epidemiologic Transition

OIE Situation Report for Avian Influenza

Global Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme

INFLUENZA-2 Avian Influenza

Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans

Understanding and Confronting Emerging Disease

Viruses: Select Agents and Emerging Pathogens. Patricia Bolívar MS., CLS, PHM

Repellent Soap. The Jojoo Mosquito. Africa s innovative solution to Malaria prevention. Sapphire Trading Company Ltd

Understanding and Confronting Emerging Disease

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva

Overview of human cases of AI H5N1 since 1997

The Threat of Agroterrorism and Zoonotic Diseases in the United States

OIE Situation Report for Avian Influenza

Planning for Pandemic Flu

Avian Influenza and Other Communicable Diseases: Implications for Port Biosecurity

AVIAN INFLUENZA. Frequently Asked Questions and Answers

Ralph KY Lee Honorary Secretary HKIOEH

Alphabet Soup of Flu Strains

University of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009

New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007

OIE Situation Report for Avian Influenza

SAFETY BULLETIN #3-05 November 11, 2005 Key Facts About Avian Influenza

Yellow fever. Key facts

EMERGING INFECTIOUS DISEASES DISCLOSURES EMERGING NONE

Current Situation on Avian Influenza and the pandemic threat

A. No. There are no current reports of avian influenza (bird flu) in birds in the U.S.

EMERGING DISEASES IN INDONESIA: CONTROL AND CHALLENGES

Health Task Force Workplan

OIE tools and global overview on Avian Influenza Dr Jocelyn Mérot OIE Sub Regional Representation for North Africa Tunis, Tunisia

European Centre for Disease Prevention and Control. Zika virus disease

OIE Situation Report for Highly Pathogenic Avian Influenza

Emerging Respiratory Infections NZ Amanda McNaughton Respiratory Physician CCDHB Wellington

AOHS Global Health. Unit 1, Lesson 3. Communicable Disease

4.3.9 Pandemic Disease

Arboviruses in Florida. Carina Blackmore, DVM, PhD Florida Department of Health Bureau of Environmental Public Health Medicine

Matt Smith. Avian Flu Model

Highly Pathogenic Avian Influenza Virus Research

Risks of Emerging Infectious Diseases in ASEAN. Prasit Palittapongarnpim, M.D. Department of Microbiology, Faculty of Science, Mahidol University

Avian influenza - current situation and future trends

Pandemic and Avian Influenza Bird flu and Beyond. Jonathan Weinstein, MD FAAP

February Emerging Infectious Diseases: The Global Picture

MI Flu Focus. Influenza Surveillance Updates Bureaus of Epidemiology and Laboratories

West Nile Virus in Maricopa County

2006 COURSE TITLE: THE BIRD FLU AND YOU

DEFINING PANDEMIC. Dr Wan Noraini Wan Mohamed Noor Head of Surveillance Sector Disease Control Division, MOH Malaysia 3 May 2018

West Nile Virus in Maricopa County

Influenza: Seasonal, Avian, and Otherwise

What we need to know about Bird Flu

CONSEQUENCES OF AVIAN INFLUENZA PANDEMIC THREAT

West Nile Virus in Maricopa County

WHO: Forum Issue #02 Student Officer Position:

One World One Health: An Economic Perspective

Regional Overview of the implementation of National Control Strategies for Avian Influenza. Summary review of questionnaire OIE RRAP

Avian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center

INFLUENZA SURVEILLANCE

Cough, Cough, Sneeze, Wheeze: Update on Respiratory Disease

Summary and Recommendations - APEC Dialogue on Avian Influenza Risks in the Live Bird Market System (LBMS)

Trends of Pandemics in the 21 st Century

Dr. Alejandro Schudel Fundación PROSAIA Argentina. 17 th IMS World Meat Congress Cape Town, South Africa, 7-10 September 2008

Suggested Exercises and Projects 395

Overview of pandemic preparedness

West Nile Virus in Maricopa County

Countries initially targeted: Bangladesh, Mongolia, Myanmar, Nepal, Lao People s Demoncratic Republic and Pakistan.

THE SITUATION OF YELLOW FEVER IN THE AFRICAN REGION: THE PLAN TO END YF EPIDEMICS IN 2026

Surveillance Protocol Dengue Fever (Breakbone fever, Dengue Hemorrhagic Fever)

AN AIRLINE EXPERIENCE OF PUBLIC HEALTH EMERGENCIES DR NIGEL DOWDALL HEAD OF AVIATION HEALTH UNIT UK CIVIL AVIATION AUTHORITY

Global Health Security: Preparedness and Response: can we do better and stay safe?

INFLUENZA WATCH Los Angeles County

Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS

Influenza B viruses are not divided into subtypes, but can be further broken down into different strains.

Agricultural Outlook Forum Presented: February 16, 2006 THE CURRENT STATE OF SCIENCE ON AVIAN INFLUENZA

Influenza A virus subtype H5N1

OIE Situation Report for Highly Pathogenic Avian Influenza

Emerging TTIs How Singapore secure its blood supply

Transcription:

Emerging Diseases

Emerging Infectious Disease Categories (NIAID) 1 of 3 Category A Priority Pathogens Category A pathogens are those organisms/biological agents that pose the highest risk to national security and public health because they: Can be easily disseminated or transmitted from person to person Result in high mortality rates and have the potential for major public health impact Might cause public panic and social disruption Require special action for public health preparedness

Emerging Infectious Disease Categories (NIAID) 2 of 3 Category B Priority Pathogens Category B pathogens are the second highest priority organisms/biological agents. They: Are moderately easy to disseminate Result in moderate morbidity rates and low mortality rates Require specific enhancements for diagnostic capacity and enhanced disease surveillance

Emerging Infectious Disease Categories (NIAID) 3 of 3 Category C Priority Pathogens Category C pathogens are the third highest priority and include emerging pathogens that could be engineered for mass dissemination in the future because of Availability Ease of production and dissemination Potential for high morbidity and mortality rates and major health impact

Relative risk of Emergence of New Pathogens Hot Spots: global distribution of relative risk of an EID event caused by zoonotic pathogens from wildlife, (Jones Nature, 2008).

JITMM, Bangkok, 12 14 December 2012

Dengue present in more than 124 countries and territories Every year: 70 to 100 million infected persons Estimated over 2 million severe forms (among which 90 % are children) Approximately 21 000 deaths Dengue There is no specific treatment and the care of the disease is based on symptomatic treatment Preventing and managing dengue is a Public Health priority!

http://www.who.int/csr/disease/dengue/impact/en/

http://www.who.int/csr/disease/dengue/impact/en/

Transmission of Dengue Mosquitoes Aedes aebypti Aedes albopictus Other Blood Transplacental Incubation: 8-12 days in mosquito

Dengue Characteristics Types DENU1, DENU2, DENU3, DENU4 Clinical Outcomes Incubation period (post-bite), 4-10 days Asymptomatic to mild disease majority Break bone fever Vomiting, headach Hemorrhagic fever severe, high cas fatality Treatment Supportive; e.g., acetaminophen No ASA Platelet replacement (hemorrhagic fever)

http://www.who.int/mediacentre/factsheets/fs117/en/

Also a food borne disease Bats (?)

SARS; the First Pandemic of 21st Century Changed the World... Screening of exit passengers WHO travel recommendations WHO travel recommendations removed 27 March 2 April 25 May 23 June Number of passenger 120000 102 165 100000 80000 60000 40000 SARS: an unknown coronavirus 8098 cases/ 774 deaths 26 countries affected trends in airline passenger movement drop Tourism dropped 40% Economic loss: US$ 60 billion 36 116 20000 0 14 670 13 May 3/16 3/19 3/22 3/25 3/28 3/31 4/3 4/6 4/9 4/12 4/15 4/18 4/21 4/24 4/27 4/30 5/3 5/6 5/9 5/12 5/15 5/18 5/21 5/24 5/27 5/30 6/2 6/5 6/8 6/11 6/14 6/17 JITMM, Bangkok, 12 14 December 2012

Clinical Characteristics of SARS High fever Headache Diarrhea (10-20%) Pneumonia Case fatality 774/8098 (10%) Treatment supportive care

Sudden Acute Respiratory Syndrome (SARS) Emerged in 2003 hotel in Hong Kong Rapid spread worldwide 8098 persons within 3-4 months Last case in 2004 Person-to-person respiratory spread droplets Source wet markets (live animals) Reservoir ferrets Agent corona virus

Can entry screening delay local transmission? Entry screening did not substantially delay local transmission ; should be balanced against the cost of implementing these measures

GONORRHEA (N. gonorrheae) #2 infectious disease in the U.S. 600,000 cases/yr (2012) Drug resistance: Penicillin 1940s Tetracycline 1980s Fluoroquinolones 2007 Cephalosporens - 2014 Next?

Gonorrhea Bolan GA, et al. The emerging threat of untreatable gonoccal infection. NEJM 366:486, 2012.

Human Avian Influenza A/H5N1 Cases by Date and Country ( 2 October 2007) 30 25 No. of cases 20 15 10 Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep 5 0 Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct 2003 Vietnam (N=100) 2004 Thailand 2005 (N=25) 2006 Cambodia (N=7) 2007 Indonesia (N=107) China (N=25) Azerbaijan (N=8) Egypt (N=38) Turkey (N=12) Iraq (N=3) Nigeria (N=1) Djibouti (N=1) Lao People's Democratic Republic (N=2) As of 2 October 2007, total of 329 cases and 201 deaths, from 12 countries, were reported.

EPIDEMIOLOGY AND BIOLOGY OF H5N1 INFLUENZA

Characteristics of H5N1 Avian Influenza 1.Highly infectious and pathogenic for domestic poultry 2.Wild fowl, ducks asymptomatic reservoir 3.Now endemic in poultry in Southeast Asia 4.Proportion of humans with subclinical infection unknown 5.Case fatality in humans is >50%

Spread of H 5 N 1 Avian Influenza South Korea Vietnam Japan Thailand Cambodia China & Laos Indonesia Resurgence in Thailand, Vietnam, Cambodia and Indonesia Europe, Africa 12 14 16 18 20 22 24 26 28 30 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 2 December, 2003 January Feb 2005-6 2006-7 2004

A New Global Concern Acknowledgment: Mike Perdue

Intervention Strategies (H5N1) Culling (killing of infected flocks) Innovative surveillance strategies - Identification and analysis of human to human clusters - Characterization of strains * Necessity for vaccine development (Science 304:968-9, 5/2004) Vaccination of bird handlers (vaccine being developed) Vaccination of commercial bird flocks

Barriers to H5N1 Control Reservoir in wild birds and ducks Economic impact of culling of poultry stocks Popularity of wet markets promotes transmission within poultry and to other species (e.g., pigs) Resistance to antivirals and vaccines Mistrust of rich nations

Don t get the flu vaccine!

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (1) Human demographic change by which persons begin to live in previously uninhabited remote areas of the world and are exposed to new environmental sources of infectious agents, insects and animals Unsustainable urbanization causes breakdowns of sanitary and other public health measures in overcrowded cities (e.g., slums)

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (2) Economic development and changes in the use of land, including deforestation, reforestation, and urbanization Global warming - climate changes cause changes in geographical distribution of agents and vectors Changing human behaviours, such as increased use of child-care facilities, sexual and drug use behaviours, and patterns of outdoor recreation Social inequality

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (3) International travel and commerce that quickly transport people and goods vast distances Changes in food processing and handling, including foods prepared from many different individual animals and countries, and transported great distances

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (4) Evolution of pathogenic infectious agents by which they may infect new hosts, produce toxins, or adapt by responding to changes in the host immunity.(e.g. influenza, HIV) Development of resistance by infectious agents such as Mycobacterium tuberculosis and Neisseria gonorrhoeae to chemoprophylactic or chemotherapeutic medicines.

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (5) Resistance of the vectors of vector-borne infectious diseases to pesticides. Immunosuppression of persons due to medical treatments or new diseases that result in infectious diseases caused by agents not usually pathogenic in healthy hosts (e.g. leukemia patients)

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (6) Deterioration in surveillance systems for infectious diseases, including laboratory support, to detect new or emerging disease problems at an early stage (e.g. Indonesian resistance to scientific colonialism ) Illiteracy limits knowledge and implementation of prevention strategies Lack of political will corruption, other priorities

FACTORS CONTRIBUTING TO EMERGENCE OR RE-EMERGENCE OF INFECTIOUS DISEASES (7) Biowarfare/bioterrorism: An unfortunate potential source of new or emerging disease threats (e.g. anthrax and letters) War, civil unrest creates refugees, food and housing shortages, increased density of living, etc. Famine causing reduced immune capacity, etc. Manufacturing strategies; e.g., pooling of plasma, etc.

STRATEGIES TO REDUCE THREATS (1) DEVELOP POLITICAL WILL AND FUNDING IMPROVE GLOBAL EARLY RESPONSE CAPACITY WHO National Disease Control Units (e.g. USCDC, CCDC) Training programs

STRATEGIES TO REDUCE THREATS (2) IMPROVE GLOBAL SURVEILLANCE Improve diagnostic capacity (training, regulations) Improve communication systems (web, e-mail etc.) and sharing of surveillance data Rapid data analysis Develop innovative surveillance and analysis strategies

STRATEGIES TO REDUCE THREATS (3) IMPROVE GLOBAL SURVEILLANCE (continued) Utilize geographical information systems Utilize global positioning systems Utilize the Global Atlas of Infectious Diseases (WHO) Increase and improve laboratory capacity Coordinate human and animal surveillance

STRATEGIES TO REDUCE THREATS (4) USE OF VACCINES Increase coverage and acceptability (e.g., oral) New strategies for delivery (e.g., nasal spray administration) Develop new vaccines Decrease cost Decrease dependency on cold chain NEW DRUG DEVELOPMENT

STRATEGIES TO REDUCE THREATS (5) DECREASE INAPPROPRIATE DRUG USE Improve education of clinicians and public Decrease antimicrobial use in agriculture and food production IMPROVE VECTOR AND ZOONOTIC CONTROL Develop new safe insecticides Develop more non-chemical strategies e.g. organic strategies BETTER AND MORE WIDESPREAD HEALTH EDUCATION (e.g., west Nile virus; bed nets, mosquito repellent)

STRATEGIES TO REDUCE THREATS (6) DEVELOPMENT OF PREDICTIVE MODELS BASED ON: Epidemiologic data Climate change surveillance Human behavior ESTABLISH PRIORITIES The risk of disease The magnitude of disease burden Morbidity/disability Mortality Economic cost REDUCE POTENTIAL FOR RAPID SPREAD DEVELOP MORE FEASIBLE CONTROL STRATEGIES

Ford TE et al. Using satellite images of environmental changes to predict infectious disease outbreaks. Emerging Infect Dis 15(9):1345, 2009.

STRATEGIES TO REDUCE THREATS (7) Develop new strategies requiring low-cost technology Social and political mobilization of communities Greater support for research Reduce poverty and inequality

BASIC ELEMENTS IN PREPAREDNESS International Health Regulations International -- WHO Global Outbreak Alert and Response Network (GOARN) 120 technical institutions participating 2000-02 -- Responded to 34 events in 26 countries Coordination of SARS and H5N1 threats Global Public Health Information Network (GPHIN)

Daily Flow of GPHIN Information 1 scanning global news 2 filtering & sorting process 3 review for relevancy 800-1000 articles selected daily Ongoing 24/7 Mon-Fri 7am-5pm EST (Hours are extended during a public health crisis)

LA Times, 28 Aug 2012

ESSENTIAL FACTORS FOR DISEASE ERADICATION Knowledge of its epidemiology and transmission patterns/mode Availability of effective tools for diagnosis, treatment and prevention Knowledge of local cultural and political characteristics Community acceptance and mobilization Political will and leadership Adequate and sustained funding

ROLE OF THE PUBLIC HEALTH PROFESSIONAL Establish surveillance for: Unusual diseases Drug resistant agents Assure laboratory capacity to investigate new agents (e.g., high-throughput labs) Develop plans for handling outbreaks of unknown agents Inform physicians about responsible antimicrobial use